Is Cerebral Amyloid-β Deposition Related to Post-stroke Cognitive Impairment?

Transl Stroke Res. 2021 Dec;12(6):946-957. doi: 10.1007/s12975-021-00921-5. Epub 2021 Jun 30.

Abstract

Approximately two-thirds of ischemic stroke patients suffer from different levels of post-stroke cognitive impairment (PSCI), but the underlying mechanisms of PSCI remain unclear. Cerebral amyloid-β (Aβ) deposition, a pathological hallmark of Alzheimer's disease, has been discovered in the brains of stroke patients in some autopsy studies. However, less is known about the role of Aβ pathology in the development of PSCI. It is hypothesized that cerebral ischemic injury may lead to neurotoxic Aβ accumulation in the brain, which further induces secondary neurodegeneration and progressive cognitive decline after stroke onset. In this review, we summarized available evidence from pre-clinical and clinical studies relevant to the aforementioned hypothesis. We found inconsistency in the results obtained from studies in rodents, nonhuman primates, and stroke patients. Moreover, the causal relationship between post-stroke cerebral Aβ deposition and PSCI has been uncertain and controversial. Taken together, evidence supporting the hypothesis that brain ischemia induces cerebral Aβ deposition has been insufficient so far. And, there is still no consensus regarding the contribution of cerebral amyloid pathology to PSCI. Other non-amyloid neurodegenerative mechanisms might be involved and remain to be fully elucidated.

Keywords: Acute ischemic stroke; Amyloid-β; Neurodegeneration; Pathogenesis; Post-stroke cognitive impairment.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Alzheimer Disease*
  • Amyloid beta-Peptides / metabolism*
  • Animals
  • Brain Ischemia* / complications
  • Cognitive Dysfunction* / etiology
  • Humans
  • Stroke* / complications

Substances

  • Amyloid beta-Peptides